Short-term Treatment Outcomes of Forrest Iib Gastric and Duodenal Ulcer Bleeding Using High-dose Intravenous Nexium
Year: 2024
Type: article
Study design: Clinical Trial
Abstract: Background: Among the causes of upper gastrointestinal bleeding, gastric and duodenal ulcers (GDU) are the most common. Forrest classification IIB (FIIB) is assessed as having a high risk of recurrent bleeding as FIA, FIB, FIIA, but treatment opinions differ. As of 2021, the European Society of Gastrointestinal Endoscopy recommends considering high-dose PPI treatment for patients in the FIIB group without endoscopic hemostasis as strong recommendation, high level of evidence. Objectives: To describe clinical and laboratory characteristics. To evaluate the short-term treatment outcomes of FIIB GDU bleeding using high-dose intravenous Nexium. Materials and methods: An uncontrolled clinical trial was conducted with 41 patients diagnosed gastrointestinal bleeding due to FIIB GDU admitted to Can Tho Central General Hospital from June 2022 to May 2024. Results: The research shows that the majority of patients responded well to treatment with high-dose intravenous Nexium (85.4%). The rates of rebleeding, surgical intervention, and mortality were relatively low at 7.3%, 2.4%, and 4.9%, respectively. Cumulative treatment failure risk was approximately 5% after 6 days of hospitalization and increased to 12.5% after 20 days of treatment. Conclusion: In patients with gastrointestinal bleeding due to FIIB peptic ulcers, treatment with high-dose intravenous Nexium has a relatively high success rate in short-term outcomes during hospitalization.
Source: Tạp chí Y học Việt Nam
Authors: The Bao Nguyen, Hieu Tam Huynh, Anh Ho Vo, Duc Tinh Vo, Dai Duong Ngo, Van Tien Phan, Cong Dang Tran, Nhat Khoa Vo, Thuy Quyen Nguyen, Thi Ngoc Huyen Le, Minh Tam Pham
Language: English
Subfield: Gastroenterology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4404858944